Pharmacological researchJul 4, 2026

Effects and Safety of GLP-1 Treatments for Heart and Metabolism Health in Children and Teens with Obesity Compared Using Network Analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 5, 2026

Abstract

Comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cardiometabolic outcomes in adolescents remain uncertain.

GLP-1RAs are used more frequently in adolescents dealing with overweight or obesity.
Key cardiometabolic parameters are being evaluated for efficacy and safety across different GLP-1RA agents.
The study focuses on adolescents with or without type 2 diabetes.
The findings could clarify the differences in effects among various GLP-1RAs.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in adolescents with overweight or obesity, but their comparative effects on cardiometabolic outcomes across different agents remain uncertain. We aimed to compare the efficacy and safety of different GLP-1RAs on key cardiometabolic parameters in adolescents with overweight or obesity, with or without type 2 diabetes.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of Competing Interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence the work submitted, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript.

PubMed

Effects and Safety of GLP-1 Treatments for Heart and Metabolism Health in Children and Teens with Obesity Compared Using Network Analysis

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief